PYPD

Company Overview — What Does PolyPid Ltd. Do?

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. PolyPid Ltd. (PYPD) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Dikla C. Akselbrad and employs approximately 80 people. With a market capitalization of $84M, PYPD is one of the notable companies in the Healthcare sector.

PolyPid Ltd. (PYPD) Stock Rating — Hold (April 2026)

As of April 2026, PolyPid Ltd. receives a Hold rating with a composite score of 38.6/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.PYPD ranks #1,652 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, PolyPid Ltd. ranks #152 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PYPD Stock Price and 52-Week Range

PolyPid Ltd. (PYPD) currently trades at $4.31. The stock lost $0.06 (1.4%) in the most recent trading session. The 52-week high for PYPD is $5.12, which means the stock is currently trading -15.8% from its annual peak. The 52-week low is $2.30, putting the stock 87.4% above its annual trough. Recent trading volume was 43K shares, suggesting relatively thin trading activity.

Is PYPD Overvalued or Undervalued? — Valuation Analysis

PolyPid Ltd. (PYPD) carries a value factor score of 14/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 0.89x, compared to the Healthcare sector average of 23.63x — a discount of 96%. The price-to-book ratio stands at 10.23x, versus the sector average of 2.75x.

At current multiples, PolyPid Ltd. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

PolyPid Ltd. Profitability — ROE, Margins, and Quality Score

PolyPid Ltd. (PYPD) earns a quality factor score of 27/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -1510.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -460.3% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

PYPD Debt, Balance Sheet, and Financial Health

PolyPid Ltd. has a debt-to-equity ratio of 113.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. Total debt on the balance sheet is $9M. Cash and equivalents stand at $16M.

PYPD has a beta of 0.65, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for PolyPid Ltd. is 65/100, reflecting average volatility within the normal range for its sector.

PolyPid Ltd. Revenue and Earnings History — Quarterly Trend

In TTM 2026, PolyPid Ltd. reported revenue of $0 and earnings per share (EPS) of $4.91. Net income for the quarter was $-29M. Operating income came in at $-28M.

In FY 2024, PolyPid Ltd. reported revenue of $0 and earnings per share (EPS) of $4.91. Net income for the quarter was $-29M. Operating income came in at $-28M.

In FY 2023, PolyPid Ltd. reported revenue of $0 and earnings per share (EPS) of $16.99. Net income for the quarter was $-24M. Operating income came in at $-23M.

In FY 2022, PolyPid Ltd. reported revenue of $0 and earnings per share (EPS) of $61.09. Net income for the quarter was $-40M. Operating income came in at $-39M.

Over the past 7 quarters, PolyPid Ltd. has experienced revenue contraction from $0 to $0. Investors analyzing PYPD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PYPD Dividend Yield and Income Analysis

PolyPid Ltd. (PYPD) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PYPD Momentum and Technical Analysis Profile

PolyPid Ltd. (PYPD) has a momentum factor score of 61/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 18/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 48/100 reflects moderate short selling activity.

PYPD vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, PolyPid Ltd. (PYPD) ranks #152 out of 838 stocks based on the Blank Capital composite score. This places PYPD in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing PYPD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PYPD vs S&P 500 (SPY) comparison to assess how PolyPid Ltd. stacks up against the broader market across all factor dimensions.

PYPD Next Earnings Date

No upcoming earnings date has been announced for PolyPid Ltd. (PYPD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PYPD? — Investment Thesis Summary

PolyPid Ltd. presents a balanced picture with arguments on both sides. The quality score of 27/100 flags below-average profitability. The value score of 14/100 indicates premium valuation. Price momentum is positive at 61/100, suggesting the trend favors buyers. Low volatility (stability score 65/100) reduces downside risk.

In summary, PolyPid Ltd. (PYPD) earns a Hold rating with a composite score of 38.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PYPD stock.

Related Resources for PYPD Investors

Explore more research and tools: PYPD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PYPD head-to-head with peers: PYPD vs AZN, PYPD vs SLGL, PYPD vs VMD.